Navigation Links
Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
Date:1/5/2009

San Diego-Based Carolus Therapeutics Focuses on Discovery and Development of Anti-Inflammatory Drugs Based on Collaborators' Findings at RWTH Aachen University in Germany

SAN DIEGO, Jan. 5 /PRNewswire/ -- Research published in Nature Medicine shows that the disruption of the interactions between two small signaling proteins called chemokines by a highly potent drug-like peptide inhibits the development of atherosclerosis in mice. San Diego-based Carolus Therapeutics Inc., which has in-licensed technology based on these and other findings of collaborators at RWTH Aachen University in Aachen, Germany, is focused on the discovery and development of drugs for the treatment of atherosclerosis and other disorders triggered by acute and chronic inflammation.

In their report, which was published online yesterday, RWTH Aachen University researchers demonstrated in a mouse model that the formation of heteromers of the chemokines platelet factor-4 (PF4, also known as CXCL4) and RANTES (CCL5) plays a regulatory role in the development of atherosclerosis. The scientists also showed that peptides designed to disrupt the formation of PF4-RANTES heteromers inhibited the development of atherosclerosis in mice that had a genetic propensity to develop the disease. (Koenen et al., Nature Med, 2009)

"Disrupting interactions between PF4 and RANTES is a novel approach to targeting inflammation that may lead to a new class of medications for the treatment of a variety of chronic and acute inflammatory diseases," said Jay Lichter, Ph.D., CEO of Carolus Therapeutics. "This approach could help to meet the unmet need for anti-inflammatory therapeutics for chronic diseases such as atherosclerosis, autoimmune diseases, rheumatoid arthritis, sepsis, asthma and multiple sclerosis."

PF4 and RANTES are chemokines that are secreted by platelets. Heteromerization of PF4 and RANTES results in recruitment of monoc
'/>"/>

SOURCE Carolus Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Six Years Recognizes Breakthrough ... Form of Heart Disease, ABBOTT PARK, Ill., Oct. ... Chicago Innovation Award for its XIENCE V(TM),Everolimus Eluting Coronary ... clinical data, the next-generation drug eluting stent,represents a significant ...
... CAMBRIDGE, Mass., Oct. 28 Peptimmune, Inc., a privately,held biotechnology ... provide an update on the Company,s current phase Ib clinical,trial ... 1. BIO Investor Forum 2008. The presentation will ... at 3:15 p.m. in the Pacific Room at the Palace ...
... DIEGO, Oct. 28 Volcano Corporation,(Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral ... results for the,third quarter and first nine months of ... hold a conference call to discuss its financial,results and ...
Cached Biology Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 2Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award 3Peptimmune Presentations at Upcoming Events 2Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:4/23/2014)... in their mid-thirties and forties, face a devastating ... two decades. "Mutant" protein clusters, long blamed for ... the primary focus of therapies in development by ... Prof. Gerardo Lederkremer and Dr. Julia Leitman of ... Immunology, in collaboration with Prof. Ulrich Hartl of ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... likelihood of an accurate group decision increases with the ... a collective faces a variety of factors as ... researchers report that smaller groups actually tend to make ... focused on only certain pieces of information. , The ... about collective intelligence, or the "wisdom of crowds," wherein ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... common, but few studies of lung nodule identification and ... from Kaiser Permanente Southern California identified 7,112 patients who ... within the electronic medical record. Their study ... Association for the Study of Lung Cancer,s (IASLC) ...
... WORCESTER, Mass. A new genetic mutation that causes ... also known as Lou Gehrig,s Disease, has been identified ... the University of Massachusetts Medical School (UMMS). Mutations to ... growth and development of nerve cell axons, is estimated ...
... new study by University of North Carolina School of Medicine ... risk for autism spectrum disorders (ASD) at 12 months received ... In addition, 85 percent of the children found to be ... Year Inventory (FYI), a 63-item questionnaire filled out by their ...
Cached Biology News:UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3Questionnaire completed by parents may help identify 1-year-olds at risk for autism 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
prototype Nco I...
Biology Products: